Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

ClinicalTrials.gov ID: NCT00632736

Public ClinicalTrials.gov record NCT00632736. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease

Study identification

NCT ID
NCT00632736
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
419 participants

Conditions and interventions

Eligibility (public fields only)

Age range
30 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2004
Primary completion
Feb 28, 2010
Completion
Feb 28, 2010
Last update posted
Mar 22, 2017

2004 – 2010

United States locations

U.S. sites
25
U.S. states
15
U.S. cities
25
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35294
GSK Investigational Site Fountain Valley California 92708
GSK Investigational Site San Francisco California 94109
GSK Investigational Site Englewood Colorado 80110
GSK Investigational Site Boca Raton Florida 33486
GSK Investigational Site Panama City Florida 32405
GSK Investigational Site Port Orange Florida 32127
GSK Investigational Site St. Petersburg Florida 33701
GSK Investigational Site Tampa Florida 33606
GSK Investigational Site Atlanta Georgia 30342
GSK Investigational Site Augusta Georgia 30912
GSK Investigational Site Glenview Illinois 60025
GSK Investigational Site Kansas City Kansas 66160
GSK Investigational Site Boston Massachusetts 02215
GSK Investigational Site Bingham Farms Michigan 48025
GSK Investigational Site Southfield Michigan 48034
GSK Investigational Site Traverse City Michigan 49684
GSK Investigational Site Albany New York 12205
GSK Investigational Site Durham North Carolina 27705
GSK Investigational Site Toledo Ohio 43614-5809
GSK Investigational Site Philadelphia Pennsylvania 19107
GSK Investigational Site Upland Pennsylvania 19013
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Wichita Falls Texas 76301
GSK Investigational Site Milwaukee Wisconsin 53233

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00632736, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 22, 2017 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00632736 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →